KBC Group NV decreased its stake in shares of Core Laboratories NV (NYSE:CLB) by 7.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 62,227 shares of the company’s stock after selling 4,712 shares during the period. KBC Group NV’s holdings in Core Laboratories NV were worth $6,990,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of CLB. Ranger Investment Management L.P. boosted its position in Core Laboratories NV by 0.8% in the second quarter. Ranger Investment Management L.P. now owns 2,565 shares of the company’s stock worth $318,000 after buying an additional 20 shares in the last quarter. Montag & Caldwell LLC boosted its position in Core Laboratories NV by 0.7% in the second quarter. Montag & Caldwell LLC now owns 4,450 shares of the company’s stock worth $551,000 after buying an additional 30 shares in the last quarter. Integrated Investment Consultants LLC boosted its position in Core Laboratories NV by 1.7% in the third quarter. Integrated Investment Consultants LLC now owns 2,314 shares of the company’s stock worth $261,000 after buying an additional 38 shares in the last quarter. BlackRock Investment Management LLC boosted its position in Core Laboratories NV by 1.4% in the second quarter. BlackRock Investment Management LLC now owns 4,915 shares of the company’s stock worth $609,000 after buying an additional 68 shares in the last quarter. Finally, Parsons Capital Management Inc. RI boosted its position in Core Laboratories NV by 3.6% in the second quarter. Parsons Capital Management Inc. RI now owns 2,150 shares of the company’s stock worth $266,000 after buying an additional 75 shares in the last quarter.

Institutional Ownership by Quarter for Core Laboratories NV (NYSE:CLB)

Shares of Core Laboratories NV (NYSE:CLB) traded up 4.922% on Wednesday, reaching $111.375. 476,553 shares of the company’s stock traded hands. Core Laboratories NV has a 12-month low of $84.50 and a 12-month high of $135.49. The stock has a 50-day moving average of $105.65 and a 200 day moving average of $114.35. The firm has a market cap of $4.91 billion, a P/E ratio of 75.457 and a beta of 1.40.

Core Laboratories NV (NYSE:CLB) last posted its earnings results on Wednesday, October 19th. The company reported $0.38 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.38. Core Laboratories NV had a net margin of 10.17% and a return on equity of 108.46%. The firm earned $143.50 million during the quarter, compared to analyst estimates of $155.72 million. During the same period last year, the firm posted $0.83 earnings per share. Core Laboratories NV’s revenue for the quarter was down 27.3% compared to the same quarter last year. On average, equities research analysts expect that Core Laboratories NV will post $1.52 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, November 22nd. Investors of record on Friday, October 21st were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.07%. The ex-dividend date was Wednesday, October 19th. Core Laboratories NV’s dividend payout ratio (DPR) is presently 149.66%.

ILLEGAL ACTIVITY NOTICE: This story was published by Financial Market News and is owned by of Financial Market News. If you are viewing this story on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this story can be accessed at http://www.financial-market-news.com/core-laboratories-nv-clb-shares-sold-by-kbc-group-nv/1210956/.

A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Core Laboratories NV from a “buy” rating to a “hold” rating in a report on Monday, September 26th. DA Davidson assumed coverage on shares of Core Laboratories NV in a report on Wednesday, October 5th. They issued a “buy” rating and a $136.00 price objective for the company. Credit Suisse Group AG assumed coverage on shares of Core Laboratories NV in a report on Thursday, September 1st. They issued a “neutral” rating and a $115.00 price objective for the company. Citigroup Inc. boosted their price objective on shares of Core Laboratories NV from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Tuesday, October 11th. Finally, Cowen and Company restated a “market perform” rating and issued a $105.00 price objective on shares of Core Laboratories NV in a report on Saturday, October 22nd. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $121.50.

About Core Laboratories NV

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

5 Day Chart for NYSE:CLB

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories NV (NYSE:CLB).

Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.